The term thiazide is universally understood to refer to diuretics that exert their principal
action in the distal tubule. The thiazide class is heterogenous and can be further subdivided …

Sodium-glucose cotransporter type 2 inhibitors (SGLT2is) are new oral glucose-lowering
agents that provide cardiovascular and renal protection in both patients with and without …

Objective Sodium-glucose cotransporter-2 inhibitors have been identified profound
renal/cardiac protective effects in different diseases. Here, we assessed the safety and …

Diabetic kidney disease (DKD) is one of the most common causes of end-stage renal
disease worldwide. The treatment of DKD is strongly associated with clinical outcomes in …

For the purpose of predicting clinical outcomes in patients with diabetes and chronic kidney
disease, change in albuminuria is a good candidate to be a surrogate marker for future …

Background Despite availability of clinical practice guidelines for hypertension
management, blood pressure (BP) control remains sub-optimal (< 30%) even in high …

A major paradigm in nephrology states that the loss of filtration function over a long time is
driven by a persistent hyperfiltration state of surviving nephrons. This hyperfiltration may …

Fluid overload secondary to loss of functional nephron mass can elevate blood pressure,
which is characteristic of hypertension shown in chronic kidney disease (CKD). Therefore, it …

Introduction Sodium-glucose co-transporter type 2 inhibitors (SGLT2is) were developed as
glucose-lowering agents for the management of type 2 diabetes (T2D). Unexpectedly, they …

Contributors EWA, MM, GF and CA contributed to the design and/or implementation of the
research and/or to the analysis of the results and to the writing and approval of the …